Search results
Results from the WOW.Com Content Network
Amisulpride is approved and used at low doses in the treatment of dysthymia and major depressive disorder. [10] [20] [11] [21] [22] [23] Whereas typical doses used in schizophrenia block postsynaptic dopamine D 2-like receptors and reduce dopaminergic neurotransmission, low doses of amisulpride preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby disinhibit dopamine ...
SEP-4199, also known as non-racemic amisulpride, is a non-racemic form of amisulpride which is under development for the treatment of bipolar depression. [ 1 ] [ 2 ] [ 3 ] It is taken by mouth . [ 1 ]
Low doses of amisulpride likewise showed anti-anhedonia-like effects. [5] ENX-104 is not expected to induce motor side effects like extrapyramidal symptoms (EPS) or catalepsy at the low doses employed, as these effects require higher occupancy of the D 2 receptor (e.g., ~80%). [5] ENX-104 is highly potent as a dopamine receptor antagonist. [5]
Amisulpride (Solian) – approved in low doses as a monotherapy for persistent depression and major depressive disorder [10] Levosulpiride – approved in low doses for major depressive disorder [11] Lumateperone (Caplyta) – approved as a monotherapy for bipolar depression; Lurasidone (Latuda) – approved as a monotherapy for bipolar depression
[7] [8] There is evidence of clozapine, amisulpride, olanzapine, and risperidone being the most effective medications. However, a high proportion of studies of risperidone were undertaken by its manufacturer, Janssen-Cilag, and should be interpreted with this in mind. [9]
This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. . Specific indications include major depressive disorder, treatment-resistant depression, dysthymia, bipolar depression, and postpartum depression, among oth
Sulpiride, sold under the brand name Dogmatil among others, is an atypical antipsychotic (although some texts have referred to it as a typical antipsychotic) [10] medication of the benzamide class which is used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and is sometimes used in low dosage to treat anxiety and mild depression.
L-741,626 is a drug which acts as a potent and selective antagonist for the dopamine receptor D 2.It has good selectivity over the related D 3 and D 4 subtypes and other receptors.